% | $
Quotes you view appear here for quick access.

Cytosorbents Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dah174174 dah174174 Aug 6, 2012 11:53 AM Flag

    2-3M share backlog to clear

    I think sales in the next report will still be tiny and this is not the parameter by which CTSO should be judged and evaluated at this juncture.
    CTSO must be evaluated by future potential which is what a decent research analyst does. If the PPS backs off due to low sales it would represent a buying opportunity. I believe the greatest potential for CTSO would be to be acquired by a deep pockets entity.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't disagree in general, but its not enough to have a good product with potential. There must be either amazing scientific validation (which CTSO does not have that we know of) or some market penetration. Otherwise, big pharma waits to see if they can get around the patents or buy them at firesale prices. By the 10Q in Nov., if they announce a meeting with the FDA to modify the IDE in prep for a US study, combined with either steady sales or at least increasing giveaways for R&D, plus maybe a PhII SBIR award, the chances of buyout on favorable terms become awesome. Without those near term milestones, maybe the buyout or partnership terms won't be what we want.

      • 2 Replies to floydtrainer
      • YES MR. DAH, i agree with your analysis. In my opinion, the big change (the zoom) will come directly after the release of the dosing-study-data (so even befor higher sales). In the mean time, "IT" will keep the PPS down by their daily, agressif short-selling (even if this takes +500.000 shortsales per day). "Its" does everything to keep the PPS down. But after the release of the new data, a bidding war will be starting and a PPS of 5 X 0,15 or 5 X 0,20 or 5 X 0,25 etc. will be given. Dont forget that the majority of the CTSO-shares are in many, many private hands and in this times, everyone can use a bonus... But dont sell yet at these ridiculous prices. We've here a really innovative, even revolutionary device, usuable for many, many different purposes and well protected by many patents. Its an one time life opportunity!!! Dont give it away!!! Its bying time; so dont sell...You will regret it deeply...

      • I see what you are saying but "...big pharma"? This is a medical device, a novel technology that is a treatment for cytokine storm (sepsis) so your criteria for a valuation may have to be altered.


6.42-0.02(-0.31%)Oct 6 4:00 PMEDT